Analyst firms · BofA Securities · KYMR

BofA Securities KYMR price target and rating history

Kymera Therapeutics Inc. (KYMR) · Health Care

BofA Securities rates Kymera Therapeutics Inc. (KYMR) Buy with a $51 price target, as of its latest action on Jun 2, 2025. It has published 4 rating actions on KYMR since September 2021, including 2 upgrades and 2 downgrades. Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.

Current rating
Buy
Price target
$51
Median target, all firms
$133
Actions on KYMR
4

BofA Securities price target on KYMR

$80$55$3020222023202420252026
BofA Securities price target on KYMR, each point a stated target, September 2021 to June 2025.

Every BofA Securities rating on KYMR

How other firms rate KYMR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Raymond JamesOutperform$140Oct 9, 2026
Wolfe ResearchOutperform$180Sep 10, 2026
Deutsche BankHold$120Jul 30, 2026
Canaccord GenuityBuy$106May 6, 2026
JefferiesBuyMar 16, 2026
BarclaysOverweight$133Jan 28, 2026

Questions about BofA Securities and KYMR

What is BofA Securities's price target for KYMR?
BofA Securities's latest stated price target for Kymera Therapeutics Inc. (KYMR) is $51, from its action on Jun 2, 2025.
What is BofA Securities's rating on KYMR?
BofA Securities rates KYMR Buy, a bullish rating, as of Jun 2, 2025.
When did BofA Securities last change its view on KYMR?
On Jun 2, 2025, BofA Securities upgrades to Buy from Neutral, price target $51.
How does BofA Securities's KYMR target compare with other analysts?
Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.

More KYMR rating histories

All BofA Securities ratingsKYMR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.